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Abstract. 
Salivary gland adenocarcinoma is a rare type of head and neck cancer and often has ag-
gressive behavior with propensity to recur and metastasize. Currently, there are no standard 
treatment guidelines. Surgery is however, the mainstay of treatment in resectable disease and 
radiation is also considered for most patients after surgery. Systemic chemotherapy is reserved 
for metastatic cases, but its results are often disappointing. Recent development of molecular 
biology has shown that salivary gland caner has several molecular changes which may guide 
potential therapeutic targets. Here, we report a 67 year-old man diagnosed to have metastasized 
minor salivary gland adenocarcinoma with diffuse human epidermal growth factor receptor-2 
(HER-2)-positive, by the immunohistochemical (IHC) stain. He was treated with a trastuzumab- 
containing chemotherapeutic regimen with encouraging results. 
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病例報告  
Trastuzumab 治療晚期第二型人類表皮生長因子受體表現陽性的唾液
腺癌 
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中文摘要 
  唾液腺腺癌是頭頸部一種少見的腫瘤，具有復發及轉移的潛在特性，所以常被視為
高惡性度。由於臨床病例不多，目前並無標準的治療方式，但開刀切除是在疾病早期可
切除時的主要治療方式，且常在開刀後建議輔以放射線治療。全身性化學治療常保留給
晚期轉移性的病患上，且治療的成績往往不夠理想。隨著分子醫學的進步，唾液腺癌被
發現經常帶有多種分子的變異，可供治療的標的。我們在此提出一個案例報告，這是一
個 67 歲男性病患，診斷為第二型人類表皮生長因子受體表現陽性的轉移性唾液腺癌，在
使用含有 trastuzumab 的處方治療後，成功有效地控制腫瘤的生長。 
 
關鍵字: 賀癌平，唾液腺癌，第二型人類表皮生長因子受體 
 
journal homepage:www.cos.org.tw/web/index.asp
台灣癌症醫誌 (J. Cancer Res. Pract.) 1(3), 220-225, 2014 DOI: 10.6323/JCRP.2014.1.3.05
Open access under CC BY-NC-ND license.
 INTRODUCTION 
Salivary gland cancers are rare, accounting for 
6~8% of all head and neck cancers [1]. Most salivary 
gland tumors are benign. In the 2005 WHO classifica-
tion, there are 24 different histologic subtypes of ma-
lignant epithelial salivary gland tumors [2]. Adenoid 
cystic carcinoma and adenocarcinoma, which origi-
nate from intercalated ducts, are two commonly seen 
subtypes. Mucoepidermoid carcinoma is derived from 
secretory ducts. Salivary gland cancers can vary from 
an indolent type to that with aggressive behavior with 
propensity to recur and metastasize [1]. Currently, 
there is no standard treatment because of its rarity. 
Treatment choices include surgery, radiation and sys-
temic chemotherapy. With the increasing understand-
ing of molecular changes of the tumors, several poten-
tial therapeutic targets were identified. Here, we report 
a 67 year-old man with metastatic left buccal minor 
salivary gland adenocarcinoma with diffuse human 
epidermal growth factor receptor-2 (HER-2)-expression, 
was successfully treated with a trastuzumab-containing 
chemotherapeutic regimen. 
 
CASE REPORT 
This 67 year-old man had been in good general 
health before he began to complain of swelling in the 
left submandibular area with tenderness in October of 
2011, lasting for more than two months. He denied 
dysphagia, dyspnea and trismus at that time. He went 
to En Chu Kong Hospital initially, where he was told 
to have salivary gland occlusion. The symptoms im-
proved gradually after medication for sialolithiasis. 
However, growing mass lesions in the left subman-
dibular area and on the left side of the neck were noted  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Neck MRI showed multiple heterogeneous 
nodules in left buccal space (A) and bone 
scan revealed suspected multiple bone 
metastatic lesions (B) 
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Figure 2. H&E stain of left buccal tumor reported 
adenocarcinoma (100 X magnification) 
 
 
later in February, 2012. He also suffered from dry 
cough, back pain and hoarseness, then. He came to our 
hospital on Feb 14th, 2012, where the local examina-
tion showed a 5 cm left submandibular tumor and level 
II 2 cm neck mass. Sonography revealed multiple en-
larged lymph nodes on the left of the neck (level IA, 
IB, II, III, IV). A core needle biopsy from the left neck 
lesion disclosed metastatic carcinoma. Neck MRI 
demonstrated multiple heterogeneous nodules in the 
left buccal space and left neck level IB, II, III (largest 
3 cm) (Figure 1A). Therefore, he underwent left buccal 
tumor excision and left modified radical neck dissec-
tion on March 5th, 2012. The pathological studies of 
both lymph nodes and left buccal tumor revealed ad-
enocarcinoma with CK-7(+), HER-2(+), BRST-2(+/-), 
TTF-1(-), P63(-) reactions (Figure 2,3). A bone scan 
revealed bone metastasis at T7, T9, L2 vertebra, ribs 
on both sides, and left pubic bone (Figure 1B). A CT 
scan disclosed right mediastinal lymphadenopathy and 
bone metastasis. Esophagogastroscopy on March 9th, 
2012, disclosed only gastric ulcer without obvious 
malignant lesions. 
Under the impression of left buccal minor salivary 
gland adenocarcinoma involving the left cervical and 
mediastinal lymph nodes, and also with bone metasta-
sis, pT2N2bM1, stage IVC, he received 4 cycles of 
palliative intravenous chemotherapy with Cisplatin/ 
high dose 5-FU and Leucovorin (P-HDFL) from 
March 19th, 2012 to June 1st, 2012. The follow-up CT 
scan on June 26th, 2012, reported mild decrease of 
tumor size and of the right mediastinal and left neck 
lymph nodes as well as left lower cheek and bone 
metastatic lesions. Therefore, intravenous chemother-
apy was switched to metronomic oral chemotherapy 
with cyclophosphamide from June 26th, 2012 to Aug 
28th, 2012. Nevertheless, the enlarging left neck 
lymph nodes with right chest wall rib pain developed 
and an elevated carcinoembryonic antigen (CEA) lev-
el was also noted in July, 2012. Palliative intravenous 
chemotherapy with P-HDFL was re-administered for a 
total of 3 cycles from Aug 31st, 2012 to Oct 19th, 2012. 
The chest wall rib pain improved gradually and the 
left neck lymph node became smaller (2.5 cm to 1.75 
cm). But his CEA and alkaline phosphatase (ALP) 
level did not decline. A bone scan on Nov 6th, 2012, 
revealed multiple new bone metastatic lesions at axial 
and appendicular skeletons. The chemotherapeutic 
regimen was switched to Paclitaxel/ Cisplatin from 
Nov 12th, 2012 to Dec 16th, 2012. However, his CEA 
level continued to increase. The chemotherapeutic 
regimen was shifted to Avastin-Paclitaxel/Cisplatin on 
Dec 26th, 2012, but without availability. The treatment 
protocol was changed to Trastuzumab-Paclitaxel/  
Cisplatin, starting on January 24th, 2013. After that, 
the CEA level began to decrease (Figure 4). However, 
the patient tolerated paclitaxel poorly. The chemo-
therapeutic regimen was therefore switched to 
Trastuzumab-Cisplatin/HDFL on March 15th, 2013. 
Later, the chemotherapy was modified to Trastuzumab- 
Carboplatin/HDFL, starting on May 6th, 2013 because 
of impaired renal function. The CEA level kept de-
creasing and the tumor size also decreased gradually. 
Thus, we considered that the patient was at last treated 
effectively with a trastuzumab-containing chemother-
apeutic regimen. 
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Figure 3. Immunohistochemical stain of left buccal tumor strongly positive for CK-7 (A) and HER-2 (B) (100 X 
magnification) 
 
 
 
 
 
 
 
 
 
 
Figure 4. CEA level decreased gradually after trastuzumab combined therapy 
 
 
DISCUSSION 
Salivary gland adenocarcinoma is one of most 
common malignant salivary gland cancers. Its prog-
nosis is poor because of its aggressive behavior with 
frequent recurrence and metastasis [1]. The experience 
with its treatment is limited because of the rarity of the 
disease. However, with rapid advances in molecular 
studies, several molecular targets, such as c-kit, epi-
dermal growth factor receptor (EGFR) and human 
epidermal growth factor receptor 2 (HER-2), were 
identified [1].  
HER-2 is a protein, encoded by the ERBB2 gene 
and is a member of epidermal growth factor (EGF) 
tyrosine kinase receptor family [3]. Overexpression of 
HER-2 protein has been shown to play an important 
role in pathogenesis of numerous cancers including 
breast, ovary, gastric, prostate and lung cancers [4-6]. 
For salivary gland cancers, HER-2 protein was also 
found over-expressed in 44% of salivary duct carci-
noma, 21% of adenocarcinoma and 2% of adenoid 
cystic carcinoma [7]. In a way similar to that of breast 
cancer, the mechanism of HER-2 protein over-    
expression in salivary gland tumor is also genomic 
amplification [8,9]. Overexpression and the increased 
gene copy number of HER-2 in salivary gland cancer 
are correlated to high-grade malignancy and unfavor-
able prognosis [10]. Several studies have shown that 
trastuzumab, a well-known agent targeting HER-2, is 
effective in treating tumors with strong HER-2 ex-
pression [11,12]. Therefore, it is reasonable to use 
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 trastuzumab in HER-2 over-expressed salivary gland 
adenocarcinoma. 
To date, there are two phase II trials using a single 
agent of HER-2 targeting- treatment for metastatic 
salivary gland neoplasm. Haddad et al., used trastu-
zumab in 14 patients with HER-2-positive salivary 
gland tumors. One patient with mucoepidermoid can-
cer had a partial response lasting for longer than two 
years [13]. Agulnik et al, used lapatinib, an orally ac-
tive dual inhibitor of EGFR and HER-2 in 62 patients 
with progressive metastatic or recurrent salivary gland 
tumors with either EGFR or HER-2 over-expression. 
Although no favorable partial response was observed, 
the treatment was well tolerated with prolonged tumor 
stabilization for at least six months in 36% of assessa-
ble patients [14]. 
Several case reports using a trastuzumab-    
containing chemotherapeutic regimen for salivary 
gland tumors were recently published. Sharon et al, 
successfully treated a 58 year-old man with HER-2- 
positive metastatic salivary gland carcinoma with 
trastuzumab, capecitabine and zoledronic acid. The 
patient experienced a complete response of his tumor 
over a two year period [15]. Kaidar-Person et al., re-
ported a 64 year-old man with HER-2-positive meta-
static salivary duct carcinoma that achieved a com-
plete response after treatment with trastuzumab, 
paclitaxel and carboplatin combination [16]. Firwana 
et al. presented a 62 year-old man with HER-2-   
positive metastatic salivary gland adenocarcinoma 
successfully treated with trastuzumab and paclitaxel 
[17]. In this report, we have presented a 67 year-old 
male patient with metastatic salivary gland adenocar-
cinoma with strong HER-2 expression. He was treated 
with a trastuzumab-containing chemotherapeutic regi-
men and showed a good response not only in imaging 
studies but also in the tumor marker survey. Moreover, 
he remained stabilized for at least six months after the 
initial treatment of trastuzumab.  
In conclusion, the expression of HER-2 oncogene 
should be examined in locally advanced or metastatic 
salivary gland carcinoma. For those tumors with 
HER-2 over-expression, the trastuzumab-containing 
chemotherapeutic regimen is a reasonable treatment 
option for this rare type of cancer. 
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